MedTrace Logo

iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions

NCT02552537 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2017-05-11

No results posted yet for this study

Summary

In patients with a walnut allergy double blind placebo controlled food challenge with walnut will be combined with the intake of proton pump inhibitor (PPI) or with placebo to assess the impact of PPI on threshold level and on clinical manifestation.

Conditions

Interventions

DRUG

Omeprazole

patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole

DRUG

Placebo

patients with walnut allergy will be exposed during 5 days before food challenge with Placebo

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • University of Nebraska Lincoln

    collaborator OTHER

  • Region Hovedstadens Apotek

    collaborator OTHER_GOV

  • University of Manchester

    collaborator OTHER

  • Hospital San Carlos, Madrid

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Clare Mills, Prof, PhD · University Manchester

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02552537 on ClinicalTrials.gov